truqap breast cancer

Release time ：Dec-26,2024

Breast cancer is a prevalent malignant tumor, with its global incidence rates escalating annually. Timely detection and intervention are crucial for enhancing the survival rates of patients with breast cancer. The truQAP breast cancer detection technology represents an innovative diagnostic approach that evaluates an individual's risk of developing breast cancer by identifying specific biomarkers in the blood. To employ the truQAP technology, a patient's blood sample must first be collected. Subsequently, specific antibodies are utilized to recognize and quantify these biomarkers, which may include, but are not limited to, CA 15-3 and CEA. By comparing these values against a normal range, a preliminary assessment can be made regarding the presence or risk of breast cancer in the patient. It is important to acknowledge that while the truQAP breast cancer detection technology offers a certain level of accuracy, it should not be considered a complete substitute for traditional breast cancer screening methods such as mammography (using a molybdenum target) and ultrasound examinations. Therefore, the use of truQAP should be complemented by other diagnostic tools to enhance the precision and comprehensiveness of the diagnosis. For individuals at high risk of breast cancer, such as those with a family history of the disease or carrying BRCA gene mutations, regular screening is especially critical. Additionally, adopting a healthy lifestyle, including a balanced diet, regular exercise, and abstaining from smoking and limiting alcohol consumption, can also contribute to reducing the risk of developing breast cancer. Should symptoms such as breast lumps, skin retraction, or nipple discharge occur, immediate medical attention is advised to receive a professional diagnosis and treatment. Throughout the treatment process, patients should adhere to the prescribed medication regimen and undergo regular check-ups to facilitate timely adjustments to the treatment plan.